318 related articles for article (PubMed ID: 27070162)
1. [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
Mukhin NA; Milovanov YS; Kozlovskaya LV; Dobrosmyslov IA; Milovanova LY
Ter Arkh; 2016; 88(4):41-45. PubMed ID: 27070162
[TBL] [Abstract][Full Text] [Related]
2. [New markers of cardio-renal links in chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
[TBL] [Abstract][Full Text] [Related]
3. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
4. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
[TBL] [Abstract][Full Text] [Related]
6. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
7. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
8. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
Ureña Torres PA
Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
[TBL] [Abstract][Full Text] [Related]
9. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
[TBL] [Abstract][Full Text] [Related]
10. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
11. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
Yilmaz MI; Sonmez A; Saglam M; Yaman H; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Yenicesu M; Mallamaci F; Zoccali C
Am J Kidney Dis; 2012 Feb; 59(2):177-85. PubMed ID: 22137672
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
13. Contemporary management of phosphorus retention in chronic kidney disease: a review.
Amiri FS
Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
[TBL] [Abstract][Full Text] [Related]
14. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
Larsson T; Nisbeth U; Ljunggren O; Jüppner H; Jonsson KB
Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
[TBL] [Abstract][Full Text] [Related]
15. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients.
Lin HH; Liou HH; Wu MS; Huang CC
BMC Nephrol; 2016 Mar; 17():33. PubMed ID: 27007989
[TBL] [Abstract][Full Text] [Related]
18. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
[TBL] [Abstract][Full Text] [Related]
19. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]